Phase I trial of low-dose interleukin 2 therapy in patients with Wiskott-Aldrich syndrome.

@article{Jyonouchi2017PhaseIT,
  title={Phase I trial of low-dose interleukin 2 therapy in patients with Wiskott-Aldrich syndrome.},
  author={Soma Jyonouchi and Brenda Gwafila and Lavesh Amar Gwalani and Maria Ahmad and Chistopher Moertel and Cecil Holbert and Ji Young Kim and Nathan L. Kobrinsky and Sumita Roy-Ghanta and Jordan S. Orange},
  journal={Clinical immunology},
  year={2017},
  volume={179},
  pages={
          47-53
        }
}
BACKGROUND Low dose IL-2 can restore the function of T and NK cells from Wiskott-Aldrich (WAS) patients. However, the safety of in vivo IL-2 in WAS is unknown. OBJECTIVES A phase-I study to assess safety of low dose IL-2 in WAS. METHODS Patients received 5 daily subcutaneous IL-2 injections, every 2months, for three courses. A "3+3" dose escalation method was used. RESULTS 6 patients received the 0.5millionunits/m2/day dose without serious adverse events. However, 2 of 3 patients… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-6 OF 6 CITATIONS

How I Manage Natural Killer Cell Deficiency

VIEW 1 EXCERPT
CITES METHODS

Low Dose Medicine: theoretical background and scientific evidence

VIEW 1 EXCERPT
CITES BACKGROUND

Tregopathies: Monogenic diseases resulting in regulatory T‐cell deficiency

VIEW 1 EXCERPT
CITES BACKGROUND

Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome

VIEW 1 EXCERPT
CITES BACKGROUND